• HCW Biologics Inc. is trading at $1.17, up 2.63% in after-hours, rebounding from recent weakness.
  • This follows the announcement on June 16, 2026, of positive preliminary human data from its Phase 1 clinical trial for HCW9302 in alopecia areata.
  • The study reported all participants in the second dose cohort showed positive clinical response and the treatment was well tolerated, with no dose-limiting toxicities.